Loading clinical trials...
Loading clinical trials...
MObile Technologies In the preVention of POSt-stroke DEPression
The recent development of acute phase treatments has dramatically improved stroke functional outcome but post-stroke neuropsychiatric disorders, notably post-stroke depression, continue to contribute to the heavy burden of stroke. While these conditions affect about 25% of stroke patients at 3 months, they are under-reported spontaneously by patients and are under-evaluated and treated by clinicians. Other than stroke severity and psychiatric history, risk factors for post-stroke depression remain a matter of debate, thus preventing identification of high-risk patients. Moreover, to date, neither pharmacological nor nonpharmacological treatments have demonstrated a significant benefit in the prevention of this disorder, thereby also impeding the development of early treatment strategies. Yet,the early management of post-stroke depression is critical given its negative influence on long-term functional outcomes, medication adherence, efficient use of rehabilitation services and the risk of stroke recurrence or vascular events. There is a pressing need to develop new tools allowing for the early detection of post-stroke neuropsychiatric complications for each individual patient. The rapid expansion of ambulatory monitoring techniques, such as Ecological Momentary Assessment (EMA), allows daily evaluations of mood symptoms in real time and in the natural contexts of daily life. The investigators have previously validated the feasibility and validity of EMA to assess daily life emotional symptoms after stroke, demonstrating its utility to investigate their evolution during the 3 months following stroke and to identify early predictors of post-stroke depression such as stress reactivity and social support, suggesting that EMA could be used in the early personalized care management of these neuropsychiatric complications. Recently, preliminary data have also emphasized the potential of EMA interventions to improve the outcome of psychiatric disorders.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
CHU de Bordeaux
Bordeaux, France
CHRU de Brest
Brest, France
CHU Dijon Bourgogne
Dijon, France
CHU de Montpellier
Montpellier, France
Assistance Publique Hopitaux de Paris - Groupe Hospitalier Paris Saint Joseph
Paris, France
Start Date
September 9, 2020
Primary Completion Date
September 26, 2024
Completion Date
March 23, 2025
Last Updated
July 20, 2025
401
ACTUAL participants
Psychological evaluation
OTHER
Functional evaluation
OTHER
Biological assessment
BIOLOGICAL
Ecological Momentary Assessment
OTHER
Lead Sponsor
University Hospital, Bordeaux
NCT07360600
NCT05093673
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07371455